课题基金 / 基金详情

eCIRP-Neutralizing mAb for Acute Lung Injury in Sepsis

eCIRP-Neutralizing mAb for Acute Lung Injury in Sepsis
eCIRP 中和单克隆抗体治疗脓毒症急性肺损伤
批准号:
10632117
负责人:
Max Brenner
金额:
$12.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-06-01 至 2023-11-30

项目摘要

项目成果

Max Brenner的其他基金

相似基金

相关文献

中文摘要
翻译
项目简介:该项目的主要目标是论证 细胞外冷诱导RNA结合蛋白(ECIRP)中和单抗的研制 #14(MAb14)作为一种治疗脓毒症合并急性肺损伤(ALI)的新方法。阿里是一个关键人物 脓毒症死亡率升高的组成部分尚未批准特定的治疗方法来减少 这类病人的死亡率。我们发现eCIRP是ALI的重要诱因,由以下原因引起 败血症和其他炎症性疾病。在我们最近的研究中,我们已经表明,增加的水平 ECIRP加重盲肠结扎穿孔(CLP)所致脓毒症小鼠的ALI。注射用 重组的eCIRP足以在其他健康的小鼠中诱导ALI。在我们的初步研究中,我们 已经产生了一大组抗eCIRP的单抗,以开发eCIRP靶向治疗 用于ALI,并筛选其对eCIRP诱导的巨噬细胞释放肿瘤坏死因子α的抑制作用。我们 然后用最有效的抗eCIRP单抗mAb14治疗CLP诱导的小鼠ALI。 与未免疫的免疫球蛋白(对照组)相比,经单抗14处理的CLP小鼠的肺组织明显变薄 炎症表现为肺组织中肿瘤坏死因子-α、白介素1β、白介素6、CXCL1和 CXCL2,以及髓过氧化物酶显示的肺内中性粒细胞浸润减少 活动。基于这些新的发现,我们假设mAb14可以作为一种新的和 治疗脓毒症引起的ALI的有效药物。在本项目中,我们将进一步测定mAb14‘S eCIRP 体外和体内的中和能力。然后我们将优化单抗14‘S的剂量以减轻脓毒症诱导的 ALI及治疗窗可提高脓毒症小鼠的存活率。我们还将评估mAb14‘S 药代动力学(PK)和药物毒性特性。我们未来的步骤将包括开发一种 人源化形式的mAb14及其ADME、PK、高级毒理学和免疫原性 学习。然后,我们将向FDA提交一份研究新药(IND)申请,以启动临床试验 目的:治疗脓毒症患者的ALI。我们的最终目标是获得mAb14的商业用途,作为一种安全 以及有效药物治疗败血症背景下的ALI患者。
英文摘要
PROJECT DESCRIPTION: The primary objective of this project is to demonstrate the feasibility of developing the extracellular cold-inducible RNA-binding protein (eCIRP)-neutralizing monoclonal antibody #14 (mAb14) as a novel treatment for septic patients with acute lung injury (ALI). ALI is a critical component of the elevated mortality rate in sepsis no specific treatment has yet been approved to reduce the mortality of such patients. We have discovered that eCIRP is a critical inducer of ALI caused by sepsis and other inflammatory diseases. In our recent studies, we have shown that increased levels of eCIRP aggravated ALI in mice with sepsis induced by cecal ligation and puncture (CLP). Injection of recombinant eCIRP was sufficient to induce ALI in otherwise healthy mice. In our preliminary studies, we have generated a large panel of anti-eCIRP monoclonal antibodies to develop an eCIRP-targeting treatment for ALI, and screened them for their inhibition of eCIRP-induced release of TNF-α by macrophages. We then used the most effective anti-eCIRP monoclonal antibody, mAb14, to treat mice with CLP-induced ALI. Compared with non-immunized IgG (control), CLP mice treated with mAb14 had attenuated lung inflammation as indicated by the decreased lung gene and protein levels of TNF-α, IL-1β, IL-6, CXCL1, and CXCL2, as well as the decreased neutrophil infiltration of the lungs as indicated by the myeloperoxidase activity. Based on these novel findings, we hypothesize that mAb14 can be developed as a new and effective drug to treat ALI caused by sepsis. In this project, we will further determine mAb14’s eCIRP neutralization ability in vitro and in vivo. We will then optimize mAb14’s dose to attenuate sepsis-induced ALI and therapeutic window to improve the survival of septic mice. We will also evaluate mAb14’s pharmacokinetics (PK) and pharmacotoxicity properties. Our future steps will include developing a humanized form of mAb14 and then conducting its ADME, PK, advanced toxicology, and immunogenicity studies. We will then file with the FDA an investigational new drug (IND) application to initiate clinical trials to treat ALI in patients with sepsis. Our ultimate goal is to obtain commercial utilization of mAb14 as a safe and effective drug to treat patients with ALI in the context of sepsis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of Ionizing Radiation in Alzheimer’s Disease
Mechanisms of Radiation-induced Vascular Endothelial Cell Injury and Its Correction
Mechanisms of Radiation-induced Vascular Endothelial Cell Injury and Its Correction
Mechanisms of Radiation-induced Vascular Endothelial Cell Injury and Its Correction
海外基金